NCT01086449View on ClinicalTrials.gov

Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

March 4, 2010

Primary Completion Date

June 25, 2010

Study Completion Date

November 25, 2010

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

Herpes Zoster Vaccine GSK 1437173A

Investigational vaccine (GSK 1437173A) administered intramuscularly.

Trial Locations (1)

2031

GSK Investigational Site, Randwick

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01086449 - Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults | Biotech Hunter | Biotech Hunter